Original InvestigationAnti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Funded by Novartis, Basel, Switzerland. The sponsor of the CANTOS trial, Novartis Pharmaceuticals, was involved in the design of the trial protocol and the collection of trial data. Dr. Everett has served as a consultant to and received grant support from Novartis for work unrelated to the CANTOS trial. Dr. Thuren is an employee of and holds stock in Novartis Pharmaceuticals. Dr. Pais has received research grant support from Novartis Pharmaceuticals to conduct the CANTOS trial. Dr. Nicolau has received research grant support from Novartis Pharmaceuticals to conduct the CANTOS trial; and has received research grants and/or personal fees from Amgen, Novartis, AstraZeneca, Bayer, Dalcor, Merck, Pfizer, and Sanofi. Dr. Glynn has received research grant support from Novartis Pharmaceuticals to conduct the CANTOS trial; and has been an unpaid consultant to Novartis. Dr. Libby has served as a consultant to Novartis. Dr. Ridker has received research grant support from Novartis Pharmaceuticals to conduct the CANTOS trial, and from Pfizer and Kowa Pharmaceuticals; has served as a consultant to Novartis; and is listed as a coinventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.